Madeleine Moussa
YOU?
Author Swipe
View article: Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial Open
Supplementary Tables 1-2
View article: Carina perforation secondary to endobronchial tuberculosis: about a case
Carina perforation secondary to endobronchial tuberculosis: about a case Open
Introduction : Carinal perforation secondary to endobronchial tuberculosis is uncommon, and even less so from other infectious causes. We report a case of carinal perforation with bronchonodal fistula secondary to tuberculosis following br…
View article: Perforation de la carène secondaire à la tuberculose endobronchique : à propos d’un cas
Perforation de la carène secondaire à la tuberculose endobronchique : à propos d’un cas Open
Introduction : Une perforation de la carène secondaire à la tuberculose endobronchique n’est pas courante, encore moins d’autres causes infectieuses. Nous rapportons un cas de perforation de la carène avec fistule broncho-nodale secondaire…
View article: Featured Cover
Featured Cover Open
View article: Renal cell carcinoma with fibromyomatous stroma (<scp>RCC FMS</scp>) and with hemangioblastoma‐like areas is part of the <scp>RCC FMS</scp> spectrum in patients with tuberous sclerosis complex
Renal cell carcinoma with fibromyomatous stroma (<span>RCC FMS</span>) and with hemangioblastoma‐like areas is part of the <span>RCC FMS</span> spectrum in patients with tuberous sclerosis complex Open
Aims Sporadic renal cell carcinomas with fibromyomatous stroma (RCC FMS) with coexistent haemangioblastoma (HB)‐like morphology have been previously reported. Such morphology has not, however, been documented in patients with tuberous scle…
View article: Les complications oculaires des allergies médicamenteuses : à propos de trois cas de syndrome de Lyell vus à l’Hôpital National de Niamey, Niger
Les complications oculaires des allergies médicamenteuses : à propos de trois cas de syndrome de Lyell vus à l’Hôpital National de Niamey, Niger Open
Introduction : La nécrolyse épidermique toxique d’origine médicamenteuse a une morbi-mortalité élevée avec des séquelles ophtalmologiques quasi-constantes chez les survivants. Les auteurs à travers ces trois cas cliniques décrivent les lés…
View article: Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial
Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial Open
Supplementary Tables 1-2
View article: Supplementary Material 1 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial
Supplementary Material 1 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial Open
Supplementary Material. Study protocol
View article: Data from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial
Data from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial Open
Purpose: Early treatment intensification with neoadjuvant therapy may improve outcomes in high-risk, localized prostate cancer (PCa) patients treated with radical prostatectomy (RP). Our objective was to compare pathologic, oncologic, and …
View article: Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial
Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial Open
Supplementary Tables 1-2
View article: Supplementary Material 1 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial
Supplementary Material 1 from Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial Open
Supplementary Material. Study protocol
View article: Pharmacological Inhibition of Endogenous Hydrogen Sulfide Production Slows Bladder Cancer Progression in an Intravesical Murine Model
Pharmacological Inhibition of Endogenous Hydrogen Sulfide Production Slows Bladder Cancer Progression in an Intravesical Murine Model Open
Present bladder cancer therapies have relatively limited therapeutic impact and account for one of the highest lifetime treatment costs per patient. Therefore, there is an urgent need to explore novel and optimized treatment strategies. Th…
View article: Evaluating the Effects of Kidney Preservation at 10 °C with Hemopure and Sodium Thiosulfate in a Rat Model of Syngeneic Orthotopic Kidney Transplantation
Evaluating the Effects of Kidney Preservation at 10 °C with Hemopure and Sodium Thiosulfate in a Rat Model of Syngeneic Orthotopic Kidney Transplantation Open
Kidney transplantation is preferred for end-stage renal disease. The current gold standard for kidney preservation is static cold storage (SCS) at 4 °C. However, SCS contributes to renal graft damage through ischemia–reperfusion injury (IR…
View article: Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial Open
Supplementary Tables 1-2
View article: Data from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
Data from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial Open
Purpose:Early treatment intensification with neoadjuvant therapy may improve outcomes in patients with high-risk, localized prostate cancer treated with radical prostatectomy. Our objective was to compare pathologic, oncologic, and safety …
View article: Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
Supplementary Tables 1-2 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial Open
Supplementary Tables 1-2
View article: Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial Open
Supplementary Material. Study protocol
View article: Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
Supplementary Material 1 from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial Open
Supplementary Material. Study protocol
View article: Data from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial
Data from Neoadjuvant Cabazitaxel plus Abiraterone/Leuprolide Acetate in Patients with High-Risk Prostate Cancer: ACDC-RP Phase II Trial Open
Purpose:Early treatment intensification with neoadjuvant therapy may improve outcomes in patients with high-risk, localized prostate cancer treated with radical prostatectomy. Our objective was to compare pathologic, oncologic, and safety …
View article: The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER).
The use of Lutetium-177 PSMA radioligand therapy with high dose rate brachytherapy for locally recurrent prostate cancer after previous definitive radiation therapy: a randomized, single-institution, phase I/II study (ROADSTER). Open
View article: Data from Characterization of the Oncogenic Activity of the Novel <i>TRIM59</i> Gene in Mouse Cancer Models
Data from Characterization of the Oncogenic Activity of the Novel <i>TRIM59</i> Gene in Mouse Cancer Models Open
A novel TRIM family member, TRIM59 gene was characterized to be upregulated in SV40 Tag oncogene–directed transgenic and knockout mouse prostate cancer models as a signaling pathway effector. We identified two phosphorylated …
View article: Data from Characterization of the Oncogenic Activity of the Novel <i>TRIM59</i> Gene in Mouse Cancer Models
Data from Characterization of the Oncogenic Activity of the Novel <i>TRIM59</i> Gene in Mouse Cancer Models Open
A novel TRIM family member, TRIM59 gene was characterized to be upregulated in SV40 Tag oncogene–directed transgenic and knockout mouse prostate cancer models as a signaling pathway effector. We identified two phosphorylated …
View article: Supplementary Methods, Figures 1-4, Tables 1-2 from Characterization of the Oncogenic Activity of the Novel <i>TRIM59</i> Gene in Mouse Cancer Models
Supplementary Methods, Figures 1-4, Tables 1-2 from Characterization of the Oncogenic Activity of the Novel <i>TRIM59</i> Gene in Mouse Cancer Models Open
Supplementary Methods, Figures 1-4, Tables 1-2 from Characterization of the Oncogenic Activity of the Novel TRIM59 Gene in Mouse Cancer Models
View article: Supplementary Methods, Figures 1-4, Tables 1-2 from Characterization of the Oncogenic Activity of the Novel <i>TRIM59</i> Gene in Mouse Cancer Models
Supplementary Methods, Figures 1-4, Tables 1-2 from Characterization of the Oncogenic Activity of the Novel <i>TRIM59</i> Gene in Mouse Cancer Models Open
Supplementary Methods, Figures 1-4, Tables 1-2 from Characterization of the Oncogenic Activity of the Novel TRIM59 Gene in Mouse Cancer Models
View article: Les Accidents Sur les Sites d’Orpaillage Traditionnel : Un Danger Pour la Vision au Niger
Les Accidents Sur les Sites d’Orpaillage Traditionnel : Un Danger Pour la Vision au Niger Open
Nous avons colligé sur 18 mois 36 yeux ayant été victimes de traumatisme chez les orpailleurs clandestins du Niger. Les atteintes étaient bilatérales dans tous les cas mais volontiers asymétriques et touchent une ou plusieurs structures de…
View article: Supplementary Figure 6 from Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound
Supplementary Figure 6 from Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound Open
Supplementary Figure 6 from Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound
View article: Supplementary Figure Legends 1-6 from Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound
Supplementary Figure Legends 1-6 from Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound Open
Supplementary Figure Legends 1-6 from Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound
View article: Data from Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound
Data from Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound Open
We report the first application of high-frequency three-dimensional power Doppler ultrasound imaging in a genetically engineered mouse (GEM) prostate cancer model. We show that the technology sensitively and specifically depicts functional…
View article: Supplementary Figure 1 from A New Three-Dimensional Ultrasound Microimaging Technology for Preclinical Studies Using a Transgenic Prostate Cancer Mouse Model
Supplementary Figure 1 from A New Three-Dimensional Ultrasound Microimaging Technology for Preclinical Studies Using a Transgenic Prostate Cancer Mouse Model Open
Supplementary Figure 1 from A New Three-Dimensional Ultrasound Microimaging Technology for Preclinical Studies Using a Transgenic Prostate Cancer Mouse Model
View article: Supplementary Figure 3 from Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound
Supplementary Figure 3 from Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound Open
Supplementary Figure 3 from Functional Neoangiogenesis Imaging of Genetically Engineered Mouse Prostate Cancer Using Three-Dimensional Power Doppler Ultrasound